Pancreatic Neoplasms

AUG 7, 2026 · OBSERVATIONAL STUDY

Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma

ClinicalTrials.gov

This is a recruiting observational tissue procurement and natural history registry with no results posted; it describes planned enrollment and sample collection methods only.

AUG 5, 2026 · JOURNAL ARTICLE

Safety, feasibility, and palliative benefit of HIFU combined with PD-1 inhibitors for elderly patients with advanced pancreatic cancer: a real-world retrospective study.

International Journal of Hyperthermia

Small retrospective single-center cohort (n=13) with no comparator arm; safety and pain relief are encouraging but survival outcomes are modest and evidence requires prospective validation.

JUL 28, 2026 · JOURNAL ARTICLE

Estimating the cost-effectiveness of tumor treating fields for locally advanced pancreatic cancer patients.

Journal of Medical Economics

Cost-utility analysis of a novel cancer therapy showing incremental QALY gain with high ICER; confirms clinical benefit translates to measurable quality-of-life improvement but at costs above conventional thresholds.

JUN 9, 2026 · JOURNAL ARTICLE

The regulatory roles of non-coding RNAs in aerobic glycolysis and therapeutic potential in pancreatic ductal adenocarcinoma.

Annals of Medicine

Narrative review summarizing mechanistic roles of non-coding RNAs in PDAC glycolysis without presenting original data or systematic meta-analysis.

MAY 19, 2026 · JOURNAL ARTICLE

UBE2C promotes pancreatic cancer progression through PI3K/Akt/mTOR signaling pathway.

Cell Cycle

This is a mechanistic cell and tissue study demonstrating that UBE2C knockdown suppresses pancreatic cancer cell behavior through PI3K/Akt/mTOR pathway inhibition, with reversal by pathway activator SC79, but lacks clinical trial data, human efficacy endpoints, or effect sizes with confidence intervals.